DNA RNA and Cells

06 Dec 2017 DNAtrix Announces First Pediatric Patient Treated with Oncolytic Virus DNX-2401
06 Dec 2017 First patient enrolled in Phase 3 trial for ATIR101™ in adult patients with blood cancer
05 Dec 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting
05 Dec 2017 Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
30 Nov 2017 Solid Biosciences Initiates Clinical Trial for Gene Transfer Candidate SGT-001 in Patients with Duchenne Muscular Dystrophy
29 Nov 2017 Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
29 Nov 2017 TWOCELLS and Chugai Announce Performing Surgery of the First Patient in Phase III Trial for “gMSC®1,” a Regenerative Cellular Medicine for Chondrogenesis in the Knee
27 Nov 2017 Eureka Announces FDA Allowance of Investigational New Drug Application for ET190L1-ARTEMIS™ T cell Therapy in Relapsed and Refractory CD19+ Non-Hodgkin Lymphoma
20 Nov 2017 U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
17 Nov 2017 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
17 Nov 2017 bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype
17 Nov 2017 Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
17 Nov 2017 Seattle Children's Opens First CAR T-Cell Immunotherapy Trial in the U.S. for Children and Young Adults With Leukemia that Targets CD22 and CD19 Proteins Simultaneously
16 Nov 2017 BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer
15 Nov 2017 Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy
15 Nov 2017 Replimune Announces First Patients Dosed in a Phase 1/2 Clinical Trial of its RP1 Oncolytic Immunotherapy in Patients With Advanced Solid Tumors
15 Nov 2017 Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit
15 Nov 2017 Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II
14 Nov 2017 Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias
13 Nov 2017 DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting
13 Nov 2017 International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson's Disease Clinical Trial
13 Nov 2017 Mesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis Patients
12 Nov 2017 Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA™ (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease
12 Nov 2017 CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting
09 Nov 2017 Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing